Influence of glucocorticoids on the osteogenic differentiation of rat bone marrow-derived mesenchymal stem cells

BMC Musculoskeletal Disorders

Jian-Jun Li³  Dan Shi¹  Cheng-Wen Wang¹  Hong-Xin Zheng²  Da-An Zhou¹ 

[1] Department of Rehabilitation, the 3rd Affiliated Hospital of Liaoning Medical University, Jinzhou 121000, China;Liaoning University of Traditional Chinese Medicine, Shenyang 110032, China;Department of Spinal and Neural Function Reconstruction, School of Rehabilitation Medicine of Capital Medical University, China Rehabilitation Research Center, No. Jiaomeibei Road Fengtai District, Beijing 100068, China

关键词: Klotho gene;    RANKL;    Osteoprotegerin;    Osteogenic differentiation capacity;    Glucocorticoid;   

Others  :  1122351
DOI  :  10.1186/1471-2474-15-239

 received in 2014-05-04, accepted in 2014-06-30,  发布年份 2014

【 摘 要 】

Background

Glucocorticoid has been used extensively in clinical applications, because of its several pharmacologic actions, which include immunosuppression, anti-inflammation, anti-shock, and relief of asthma. However, the long-term or high-dose application of glucocorticoid can induce adverse effects such as osteoporosis, which is known in this case as glucocorticoid-induced osteoporosis (GIOP). It is a secondary osteoporosis that results in easy fracturing, and even disability. Therefore it became a thorny issue.

Methods

The rat model of glucocorticoid-induced osteoporosis (GIOP) was replicated to isolate BMSCs. Rats were assigned into four groups: normal, normal induction, GIOP, and GIOP induction. The growth cycle was monitored by using flow cytometry. Osteogenic differentiation was compared by using alkaline phosphatase (ALP) staining with a modified calcium cobalt method. The quantitative detection of osteoprotegerin and the receptor activator of nuclear factor kappa-B ligand (RANKL) was conducted by using enzyme-linked immunoassay. Finally, renal Klotho mRNA expression was assessed by using RT-PCR.

Results

BMSC proliferation was reduced in GIOP rats. The ALP-positive expression of normal BMSCs to the osteogenic induction solution was stronger than that of BMSCs from GIOP rats (P < 0.01). Osteoprotegerin expression was significantly higher in the normal induction group than in the normal, GIOP (P < 0.01), and GIOP induction groups (P < 0.05). RANKL expression was significantly higher in the normal induction group than in the other groups (P < 0.01) and significantly higher in the normal group than in the GIOP and GIOP induction groups (P < 0.01). RT-PCR analysis showed that renal Klotho mRNA expression was significantly reduced in the GIOP group compared with the normal group (P < 0.01).

Conclusion

BMSC proliferation, osteogenic differentiation, and reactive activity to an osteogenic inductor were reduced in GIOP rats. Klotho mRNA expression decreased during GIOP induction.

【 授权许可】

   
2014 Zhou et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Canalis E, Mazziotti G, Giustina A, Bilezikian JP: Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 2007, 18:1319-1328.
• [2]Bouxsein ML, Kaufman J, Tosi L, Cummings S, Lane J, Johnell O: Recommendations for optimal care of the fragility fracture patient to reduce the risk of future fracture. J Am Acad Orthop Surg 2004, 12:385-395.
• [3]Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C: Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000, 15:993-1000.
• [4]Ahdjoudj S, Fromigue O, Marie PJ: Plasticity and regulation of human bone marrow stromal osteoprogenitor cells: potential implication in the treatment of age-related bone loss. Histol Histopathol 2004, 19:151-157.
• [5]Jin MZ, Zheng HX: Bone marrow fat cells and osteoporosis. Chin J Osteoporos 2006, 12:645-648.
• [6]Uemura T, Dong J, Wang Y, Kojima H, Saito T, Iejima D, Kikuchi M, Tanaka J, Tateishi T: Transplantation of cultured bone cells using combinations of scaffolds and culture techniques. Biomaterials 2003, 24:2277-2286.
• [7]Liu F, Han H: Characteristics of rat bone marrow stroma stem cells and its differentiation to osteoblast. J Med Mol Biol 2004, 1:73-76.
• [8]Tian L, Liang M, Zhang J, Xian J, Huang S, Jinwei C, Luo Z: Construction of osteoporosis rats model induced by glucocorticiod. Guangxi Medical University J 2013, 30:5-6.
• [9]Wang J, Zheng HX, Zong ZHH, Li K, Yang F, Zhu H, Zhang G: Comparative research of the expression of osterix mrna and protein of bone tissue after using traditonal Chinese medicine to invigorate osteoporosis rats’ kindney, spleen and blood induced by glucocorticoid. China J Tradit Chin Med Pharm 2011, 26:801-806.
• [10]Sammons J, Ahmed N, El-Sheemy M, Hassan HT: The role of BMP-6, IL-6, and BMP-4 in mesenchymal stem cell-dependent bone Development; effects on osteoblastic differentiation induced by parathyroid hormone and vitamin D(3). Stem Cells Dev 2004, 13:273-280.
• [11]Cao J, Venton L, Sakata T, Halloran BP: Expression of rank and OPG correlates with age-related bone loss in male C57Bl/6 mice. J Bone Res 2003, 18:270-272.
• [12]Kostenuik PJ, Morony S, Capparelli C, Adamu S, Shimamoto G, Shen V, Lacey DL, Dunstan CR: OPG and PTH (1–34) have additive efects on bone density and mechanical strength in osteopenic ovariectomized rats. Endocrinology 2001, 142:4295-4304.
• [13]Hughes AE, Ralston SH, Marken J, Bell C, MacPherson H, Wallace RG, van Hul W, Whyte MP, Nakatsuka K, Hovy L, Anderson DM: Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nat Genet 2000, 24:45-48.
• [14]Ikeda T, Utusuyma M, Hirokawa K: Expression profiles of receptor activator of nuclear factor kB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones. J Bone Miner Res 2001, 16:1416-1425.
• [15]Kuro-o M, Matsunura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, Iwasaki H, Iida A, Shiraki-Iida T, Nishikawa S, Nagai R, Nabeshima YI: Mutation of the mouse Klotho gene leads to a syndrome resembling ageing. Nature 1997, 390:45-51.
• [16]Xiao NM, Zhang YM, Zheng Q, Gu J: Klotho is a serum factor related to human aging. Chin Med J (Engl) 2004, 117:742-747.
• [17]Nabeshima Y: Klotho: a fundamental regulator of aging. Ageing Res Rev 2002, 1:627-638.
• [18]Kurosu H, Yamamoto M, Clark JD, Pastor JV, Nandi A, Gurnani P, McGuinness OP, Chikuda H, Yamaguchi M, Kawaguchi H, Shimomura I, Takayama Y, Herz J, Kahn CR, Rosenblatt KP, Kuro-o M: Suppression of aging in mice by the hormone Klotho. Science 2005, 309:1829-1833.